ReviewFrontiers in immunology2022
Subunit vaccines for
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Combatting Salmonella: a focus on antimicrobial resistance and the need for effective vaccination.BMC infectious diseases · 2025Pooled it
- Design of a live-attenuated bacterial vaccine using effector network engineering.Nature communications · 2026Article
- Virulence and Resistance Mechanisms in Multidrug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Review
- A mutation-aware proteomics approach for designing a multi-epitope vaccine against multidrug-resistantMicrobiology spectrum · 2026Article
- The Role of Combination Antibiotic Therapy in Combatting Drug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Generation and Evaluation of a Multi-Epitope Vaccine AgainstVaccines · 2026Article
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
- Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens.Pathogens (Basel, Switzerland) · 2025Review
- Article
- The evolution of the multidrug-resistant and globally distributed ST2 Acinetobacter baumannii in China.BMC microbiology · 2025Article
- Intranasal delivery of mRNA expressing newly identified Acinetobacter baumannii antigens protects against bacterial lung disease.NPJ vaccines · 2025Article
- Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control-A Narrative Review.Infectious diseases and therapy · 2025Review
- Epitope-Based Vaccines: The Next Generation of Promising Vaccines Against Bacterial Infection.Vaccines · 2025Review
- Omp34-MediatedAnalytical cellular pathology (Amsterdam) · 2025Article
- Nanotechnology-based strategies for vaccine development: accelerating innovation and delivery.Biomaterials translational · 2025Review
- In silico design and assessment of a multi-epitope peptide vaccine against multidrug-resistantIn silico pharmacology · 2025Article
- Humoral response induced after intranasal vaccination with heat inactivatedFrontiers in immunology · 2025Article
- Inserting Omp22 into the flagellin protein, replacing its hypervariable region, results in stronger protection against lethal Acinetobacter baumannii infection.Scientific reports · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.